Array Biopharma, Inc. (ARRY) Posts Q4 Loss of 9c/Share, Narrower than Views
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.06 -4.25%
EPS Growth %: -70.0%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -70.0%
Financial Fact:
Cost of revenue: 8.85M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q4 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $21.45 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Redburn upgrades Southwest, stays bullish on Delta and United
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
